CONTEXT: Commercial announcement of RWD use in angioedema
IMPACT: low
READ TIME: 1 min
Quality Level Mean [1 – 10]: 5
1. “ICER’s updated assessment will leverage observational RWE analyzed by Aetion, as part of the ongoing collaboration between the two organizations , and consistent with ICER’s to expand use of RWE to complement other sources of information used in its value assessments.”
2. “By defining the baseline demographics and utilization characteristics of patients who start HAE prophylaxis, evaluating HAE attack rates before initiation of prophylaxis, and updating our health cost assumptions accordingly, ICER aims to further clarify the overall value of these HAE therapies in real-world settings.”
3. “We appreciate Aetion’s continued partnership as we work together to set new standards for how decision-grade RWE can be appropriately applied alongside high-quality clinical trial data to better inform the consequential decisions that biopharma manufacturers, insurers, and other stakeholders make every single day around drug pricing and patient access.””
4. “”We commend ICER for continuing to improve the ways in which RWE can be integrated responsibly into US health technology assessment,” said Carolyn Magill, CEO of Aetion.”
5. “ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.”